Rathbones Group PLC purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,883 shares of the exchange traded fund’s stock, valued at approximately $473,000.
Several other hedge funds have also added to or reduced their stakes in the business. Dynamic Wealth Strategies LLC lifted its stake in SPDR S&P Biotech ETF by 3.8% in the fourth quarter. Dynamic Wealth Strategies LLC now owns 2,201 shares of the exchange traded fund’s stock worth $268,000 after purchasing an additional 80 shares during the last quarter. Capital Investment Advisory Services LLC lifted its stake in SPDR S&P Biotech ETF by 4.0% in the fourth quarter. Capital Investment Advisory Services LLC now owns 2,123 shares of the exchange traded fund’s stock worth $259,000 after purchasing an additional 81 shares during the last quarter. Compass Ion Advisors LLC lifted its stake in SPDR S&P Biotech ETF by 2.6% in the fourth quarter. Compass Ion Advisors LLC now owns 3,886 shares of the exchange traded fund’s stock worth $474,000 after purchasing an additional 97 shares during the last quarter. Moors & Cabot Inc. lifted its stake in SPDR S&P Biotech ETF by 3.8% in the third quarter. Moors & Cabot Inc. now owns 2,717 shares of the exchange traded fund’s stock worth $272,000 after purchasing an additional 100 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in shares of SPDR S&P Biotech ETF by 3.1% during the third quarter. Sequoia Financial Advisors LLC now owns 3,393 shares of the exchange traded fund’s stock valued at $340,000 after acquiring an additional 101 shares during the last quarter.
SPDR S&P Biotech ETF Trading Down 0.8%
Shares of NYSEARCA:XBI opened at $131.66 on Friday. The company has a market cap of $8.40 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85. The company has a 50-day moving average price of $129.82 and a 200-day moving average price of $125.05. SPDR S&P Biotech ETF has a 12 month low of $78.00 and a 12 month high of $139.19.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
